On November 28, Gracell Pharmaceuticals announced that XWIO (selinexor tablets) has added a new indication to the national medical insurance catalog, with medical insurance coverage for adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who have previously received at least two lines of systemic therapy. The new version of the national medical insurance catalog will officially take effect on January 1, 2025. In July 2024, after initially being approved for the treatment of relapsed or refractory multiple myeloma (R/R MM), XWIO obtained its second indication in China for the treatment of R/R DLBCL. Up to now, both indications approved for XWIO in China have been included in the national medical insurance catalog, expanding the coverage of medical insurance beneficiaries. XWIO is the world's first novel oral selective XPO1 inhibitor and has been approved for multiple indications in 9 countries and regions in the Asia-Pacific market, with medical insurance coverage achieved in 4 markets including mainland China, Australia, Singapore, and South Korea. The company expects to achieve medical insurance coverage in more Asia-Pacific markets in the future.